Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells.
Guinea pig erythrocytes that had been exposed to influenza A virus activated the alternative complement pathway in whole human serum in the absence of natural antibodies. Because all virus particles were eluted from the treated cells, activation was not dependent on antiviral antibodies or on virus particles themselves. The relative capacity of treated erythrocytes to activate the alternative pathway was dependent on the amount of virus to which the cells had been exposed and was directly related to the amount of sialic acid removed from the erythrocyte membrane during incubation with either whole virus particles or purified viral sialidase. C3b bound to cells that had been treated with virus, and P-stabilized amplification convertase sites P,C3b,Bb formed on these cells, exhibited increased resistance to the action of the regulatory proteins beta-1H and C3b Ina compared with C3b and P,C3b,Bb on untreated, nonactivating cells. The acquired resistance of the cell-bound, P-stabilized amplification convertase to decay-dissociation by beta-1H was directly related to the activating capacity of the treated cells in whole serum (r = 0.95) and to the amount of sialic acid removed from the cells by the virus (r = 0.98). Desialation represents a specific alteration of the cell surface by which a nonimmune host, through activation of the alternative pathway, may deposit C3b on a target cell that had been exposed to influenza virus and may lyse virus virus-modified cells during orthomyxovirus infections.
D000818:Animals; D003167:Complement Activation; D003176:Complement C3 / Q000276:immunology; D003179:Complement C3b / Q000276:immunology; D003180:Complement C3b Inactivator Proteins / Q000276:immunology; D015932:Complement C3c; D017242:Complement Factor H; D003170:Complement Pathway, Alternative; D004306:Dose-Response Relationship, Immunologic; D004910:Erythrocyte Membrane / Q000201:enzymology; D004912:Erythrocytes / Q000276:immunology* / Q000648:ultrastructure; D006168:Guinea Pigs; D006801:Humans; D009980:Influenza A virus / Q000276:immunology*; D009439:Neuraminidase / Q000494:pharmacology; D011414:Properdin / Q000276:immunology; D012794:Sialic Acids / Q000378:metabolism*
C493495:CFH protein, human; D003176:Complement C3; D003180:Complement C3b Inactivator Proteins; D012794:Sialic Acids; D011414:Properdin; D003179:Complement C3b; D015932:Complement C3c; D017242:Complement Factor H; D009439:Neuraminidase